Bioventus Reports First Quarter Financial Results
Bioventus Inc. reported solid financial results for Q1 2026, with revenue increasing 7% to $132.1 million driven by growth across its Pain Treatments, Surgical Solutions, and Restorative Therapies segments. GAAP earnings improved to $0.04 per diluted share from a prior year loss, and non-GAAP earnings nearly doubled to $0.15 per diluted share. The …